Apogee Therapeutics, Inc. (APGE)
89.54
+6.82
(+8.24%)
USD |
NASDAQ |
Jun 11, 16:00
89.54
0.00 (0.00%)
After-Hours: 18:14
Apogee Therapeutics Total Liabilities (Quarterly) : 37.86M for March 31, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 37.86M |
| December 31, 2025 | 33.25M |
| September 30, 2025 | 39.82M |
| June 30, 2025 | 38.37M |
| March 31, 2025 | 40.80M |
| December 31, 2024 | 37.16M |
| September 30, 2024 | 41.88M |
| Date | Value |
|---|---|
| June 30, 2024 | 27.02M |
| March 31, 2024 | 22.18M |
| December 31, 2023 | 21.49M |
| September 30, 2023 | 17.18M |
| June 30, 2023 | 17.62M |
| March 31, 2023 | 11.19M |
| December 31, 2022 | 9.98M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Evommune, Inc. | 17.90M |
| Cogent Biosciences, Inc. | 295.31M |
| Kymera Therapeutics, Inc. | 129.38M |
| Erasca, Inc. | 67.71M |
| GRAIL, Inc. | 302.79M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 1.294B |
| Shareholders Equity (Quarterly) | 1.256B |
| Debt to Equity Ratio | 0.0064 |
| Current Ratio | 32.59 |
| Net Debt Paydown Yield | 0.01% |